Manochakian/X
Dec 28, 2024, 18:09
Rami Manochakian: FDA approved subcutaneous Nivolumab for Solid Tumors
Rami Manochakian, Thoracic medical oncologist at Mayo Clinic, shared a post on X:
“U.S FDA approved Subcutaneous Nivolumab for:
- All adult indications in Solid Tumors.
- Except for a combination with Ipilimumab.
Approval based on CHECKMATE 67T which showed similar Efficacy and Safety of SQ vs IV.”
Dr. Rami Manochakian is a thoracic medical oncologist at Mayo Clinic, Florida. He specializes in thoracic malignancies, including lung cancer, mesothelioma, and thymic tumors, he has dedicated his career to advancing the field of oncology. He is also recognized as a leader in medical education, serving in various educational roles at Mayo Clinic and national and international medical societies, including ASCO, ALA, and IASLC.
More posts featuring Rami Manochakian.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 29, 2024, 15:44
Dec 29, 2024, 15:34
Dec 29, 2024, 15:28
Dec 29, 2024, 15:25
Dec 29, 2024, 15:12
Dec 29, 2024, 13:48
Dec 29, 2024, 13:46
Dec 29, 2024, 13:44
Dec 29, 2024, 13:42